Werewolf Therapeutics (HOWL) announced that the Company has received Fast Track Designation, FTD, for the use of WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous melanoma after standard of care immunotherapy. WTX-124 is a conditionally activated interleukin 2 INDUKINE therapy. Fast Track Designation is intended to expedite the development of drugs to address a serious unmet medical need and provide opportunities for frequent FDA interactions.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics Faces Nasdaq Compliance Challenge
- Werewolf Therapeutics price target lowered to $8 from $9 at BofA
- Werewolf Therapeutics price target lowered to $3 from $4 at Citizens JMP
- Promising Advancements in Werewolf Therapeutics’ Drug Pipeline Support Buy Rating
- Werewolf Therapeutics Faces Regulatory and Financial Challenges Amid FDA Disruptions